Sector News

Categories

Borderless Insights

Image
Negotiating Terms with a New Employer
Image
Beyond Flowers and Platitudes: Reclaiming the Essence of International Women’s Day
Image
Visionary or ‘Stuck-in-the-Mud’? Where are you on Workplace Flexibility?

Merck appoints Udit Batra to head combined life science business

April 14, 2015
Life sciences
Merck has appointed Udit Batra, currently Chief Executive Officer and President, Merck Millipore, to lead the combined life science business of Merck Millipore and Sigma-Aldrich once the acquisition of Sigma-Aldrich has been successfully completed.
 
The planned $17 billion transaction remains subject to customary closing conditions and regulatory approvals, which the company expects to have completed in mid-2015. Until then, Merck Millipore and Sigma-Aldrich will continue to operate as separate companies with Udit Batra and Rakesh Sachdev, President and Chief Executive Officer, Sigma-Aldrich, running both organisations independently. Rakesh Sachdev will serve in an advisory capacity, as needed, to ensure a smooth transition.
 
Udit Batra, 44, has served as the Chief Executive Officer and President, Merck’s life science business Merck Millipore since March 2014. He joined Merck in 2011 to head the Group’s Consumer Health business. Prior to that, Udit Batra worked at Novartis Vaccines and Diagnostics, where he was head of global public health and market access. He served in a range of executive management positions at Novartis, including global Head of Corporate Strategy and Country President for the Pharma Business in Australia.
 
Karl-Ludwig Kley, Chairman of the Executive Board of Merck, said, “Udit is a proven leader who has demonstrated his ability to work successfully with his leadership team to guide large organisations, drive performance and deliver to our customers. I also want to express my gratitude to the Sigma-Aldrich employees for building the organisation into a leading global life science tools company and to Rakesh, personally, for providing excellent leadership to the Sigma-Aldrich organisation, both culturally and as demonstrated by the company’s strong performance.”
 

comments closed

Related News

April 20, 2024

CureVac and MD Anderson Cancer Center partner to develop new cancer vaccines

Life sciences

CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.

Read more
April 20, 2024

FUJIFILM plans $1.2 billion investment in major US manufacturing facility

Life sciences

FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.

Read more
April 20, 2024

Sanofi cuts staff in Belgium as early-stage research dwindles

Life sciences

Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.

Read more
More news

How can we help you?

We're easy to reach